HUMANIZED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1

Title:

HUMANIZED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1

Document Type and Number:

WIPO Patent Application WO/2017/014679

Kind Code:

A3

Abstract:

The present invention relates to immunology, biotechnology and medicine, notably to the field of antitumor pharmaceuticals based on monoclonal antibodies, and can be used in medicine for the treatment of oncological diseases. The object of the invention was to create an efficient and safe universal antitumor agent, the production of which effective, quick and easy. This problem is solved by the proposed humanized monoclonal antibody specific to syndecan-1, of the IgG4 isotype, or with IgG3 fragments and amino acid substitutions for the increase the antibody half-life, characterized by a definite combination of the calculated and created by the authors amino acid and nucleotide sequences, which is used as a self-acting substance for the therapy of tumor diseases. Nucleotide sequences additionally contain a fragment coding for a signal secretory sequence at the N- terminus, and are codon-optimized to increase antibody production in mammalian cells.

More Like This:

WO/2010/027797	T-CELL RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
WO/2024/077069	MONOCLONAL ANTIBODIES AGAINST HUMAN PROGRAMMED CELL DEATH PROTEIN 1 (PD-1)
JP2975679	Description: Structural changes in the EGF receptor gene of human glioma

Inventors:

DUKHOVLINOV ILYA VLADIMIROVICH (RU)
ORLOV ANTON IOSIFOVICH (RU)
BALAZOVSKIY MARK BORISOVICH (RU)
SPEKTOR GENE MIRON (RU)

Application Number:

PCT/RU2016/000467

Publication Date:

March 23, 2017

Filing Date:

July 21, 2016

Export Citation:

Click for automatic bibliography generation Help

Assignee:

DUKHOVLINOV ILYA VLADIMIROVICH (RU)
ORLOV ANTON IOSIFOVICH (RU)
BALAZOVSKIY MARK BORISOVICH (RU)
SPEKTOR GENE MIRON (RU)

International Classes:

C07K16/28; C12N15/13

Domestic Patent References:

WO2009080829A1

2009-07-02

Foreign References:

US20070183971A1	2007-08-09
RU2486203C2	2013-06-27

Other References:

TASSONE P. ET AL.: "Cytotoxic activity of the maytansinoid immunoconjugate B-B4- DM1 against CD 138+ multiple myeloma cells.", BLOOD, vol. 104, no. 12, 2004, pages 3688 - 3696, XP002521112
See also references of EP 3325511A4

Attorney, Agent or Firm:

FEDOROVA, Ekaterina Alekseevna (RU)

Download PDF:

View/Download PDF PDF Help

Previous Patent: SHIP (VARIANTS)

Next Patent: METHOD FOR DISPLAYING OBJECT ON THREE-DIMENSIONAL MODEL